Protara Therapeutics Announces 2026 Annual Meeting Results and Increase in Authorized Shares

Protara Therapeutics, Inc. reported the results of its Annual Meeting of Stockholders held on June 12, 2026. Stockholders elected three Class III directors—Jesse Shefferman, Barry Flannelly, Pharm.D., and Cynthia Smith—to serve until the 2029 Annual Meeting. Additionally, stockholders ratified the selection of Ernst and Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Key corporate governance updates were also approved, including an amendment to the Company’s Sixth Amended and Restated Certificate of Incorporation to double the number of authorized shares of common stock from 100,000,000 to 200,000,000. Other approved measures included an amendment to the 2024 Equity Incentive Plan, an advisory vote in favor of executive compensation ('say-on-pay') to occur annually, and an amendment allowing for officer exculpation as permitted by Delaware law. As of the record date, 55,060,500 shares were outstanding and entitled to vote.